Zika virus Infections-Pipeline Review, H1 2017

Zika virus Infections-Pipeline Review, H1 2017


  • Products Id :- GMDHC9451IDB
  • |
  • Pages: 177
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Zika virus Infections-Pipeline Review, H1 2017

Summary

Global Markets Direct latest Pharmaceutical and Healthcare disease pipeline guide Zika virus Infections-Pipeline Review, H1 2017, provides an overview of the Zika virus Infections (Infectious Disease) pipeline landscape.

Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Zika virus is a member of the Flaviviridae family. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

Report Highlights

Global Markets Direct Pharmaceutical and Healthcare latest pipeline guide Zika virus Infections-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Zika virus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Zika virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Zika virus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 32 and 26 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 6 and 5 molecules, respectively.

Zika virus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Zika virus Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Zika virus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Zika virus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Zika virus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Zika virus Infections (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Zika virus Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Zika virus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

Introduction 5

Zika virus Infections-Overview 6

Zika virus Infections-Therapeutics Development 7

Zika virus Infections-Therapeutics Assessment 18

Zika virus Infections-Companies Involved in Therapeutics Development 26

Zika virus Infections-Drug Profiles 48

Zika virus Infections-Dormant Projects 157

Zika virus Infections-Product Development Milestones 158

Appendix 168

List of Figures

Number of Products under Development for Zika virus Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Zika virus Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Zika virus Infections-Pipeline by Acuitas Therapeutics Inc, H1 2017

Zika virus Infections-Pipeline by Bharat Biotech International Ltd, H1 2017

Zika virus Infections-Pipeline by BioCryst Pharmaceuticals Inc, H1 2017

Zika virus Infections-Pipeline by Biotron Ltd, H1 2017

Zika virus Infections-Pipeline by CaroGen Corp, H1 2017

Zika virus Infections-Pipeline by Cocrystal Pharma Inc, H1 2017

Zika virus Infections-Pipeline by Emergent BioSolutions Inc, H1 2017

Zika virus Infections-Pipeline by Ennaid Therapeutics LLC, H1 2017

Zika virus Infections-Pipeline by Etubics Corp, H1 2017

Zika virus Infections-Pipeline by GeneOne Life Science Inc, H1 2017

Zika virus Infections-Pipeline by GeoVax Labs Inc, H1 2017

Zika virus Infections-Pipeline by Gilead Sciences Inc, H1 2017

Zika virus Infections-Pipeline by Hawaii Biotech Inc, H1 2017

Zika virus Infections-Pipeline by Heat Biologics Inc, H1 2017

Zika virus Infections-Pipeline by Hemispherx Biopharma Inc, H1 2017

Zika virus Infections-Pipeline by Humabs BioMed SA, H1 2017

Zika virus Infections-Pipeline by Immunovaccine Inc, H1 2017

Zika virus Infections-Pipeline by Kineta Inc, H1 2017

Zika virus Infections-Pipeline by Mymetics Corp, H1 2017

Zika virus Infections-Pipeline by NewLink Genetics Corp, H1 2017

Zika virus Infections-Pipeline by Novalex Therapeutics Inc, H1 2017

Zika virus Infections-Pipeline by Novavax Inc, H1 2017

Zika virus Infections-Pipeline by OXIS International Inc, H1 2017

Zika virus Infections-Pipeline by PaxVax Inc, H1 2017

Zika virus Infections-Pipeline by Plex Pharmaceuticals Inc, H1 2017

Zika virus Infections-Pipeline by Profectus BioSciences Inc, H1 2017

Zika virus Infections-Pipeline by Prokarium Ltd, H1 2017

Zika virus Infections-Pipeline by Protein Sciences Corp, H1 2017

Zika virus Infections-Pipeline by Regeneron Pharmaceuticals Inc, H1 2017

Zika virus Infections-Pipeline by Replikins Ltd, H1 2017

Zika virus Infections-Pipeline by Sanofi Pasteur SA, H1 2017

Zika virus Infections-Pipeline by Sirnaomics Inc, H1 2017

Zika virus Infections-Pipeline by Spotlight Innovation Inc, H1 2017

Zika virus Infections-Pipeline by Starpharma Holdings Ltd, H1 2017

Zika virus Infections-Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Zika virus Infections-Pipeline by Tamir Biotechnology Inc, H1 2017

Zika virus Infections-Pipeline by TechnoVax Inc, H1 2017

Zika virus Infections-Pipeline by Themis Bioscience GmbH, H1 2017

Zika virus Infections-Pipeline by Theravectys SA, H1 2017

Zika virus Infections-Pipeline by Valneva SE, H1 2017

Zika virus Infections-Pipeline by Vaxart Inc, H1 2017

Zika virus Infections-Pipeline by VBI Vaccines Inc, H1 2017

Zika virus Infections-Pipeline by Visterra Inc, H1 2017

Zika virus Infections-Pipeline by VLP Therapeutics LLC, H1 2017

Zika virus Infections-Dormant Projects, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Acuitas Therapeutics Inc

Bharat Biotech International Ltd

BioCryst Pharmaceuticals Inc

Biotron Ltd

CaroGen Corp

Cocrystal Pharma Inc

Emergent BioSolutions Inc

Ennaid Therapeutics LLC

Etubics Corp

GeneOne Life Science Inc

GeoVax Labs Inc

Gilead Sciences Inc

Hawaii Biotech Inc

Heat Biologics Inc

Hemispherx Biopharma Inc

Humabs BioMed SA

Immunovaccine Inc

Kineta Inc

Mymetics Corp

NewLink Genetics Corp

Novalex Therapeutics Inc

Novavax Inc

OXIS International Inc

PaxVax Inc

Plex Pharmaceuticals Inc

Profectus BioSciences Inc

Prokarium Ltd

Protein Sciences Corp

Regeneron Pharmaceuticals Inc

Replikins Ltd

Sanofi Pasteur SA

Sirnaomics Inc

Spotlight Innovation Inc

Starpharma Holdings Ltd

Takeda Pharmaceutical Company Ltd

Tamir Biotechnology Inc

TechnoVax Inc

Themis Bioscience GmbH

Theravectys SA

Valneva SE

Vaxart Inc

VBI Vaccines Inc

Visterra Inc

VLP Therapeutics LLC

Zika Virus Infections Therapeutic Products under Development, Key Players in Zika Virus Infections Therapeutics, Zika Virus Infections Pipeline Overview, Zika Virus Infections Pipeline, Zika Virus Infections Pipeline Assessment

select a license
Single User License
USD 2000 INR 138000
Site License
USD 4000 INR 276000
Corporate User License
USD 6000 INR 414000

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com